Products Suvorexant was approved in the United States in 2014 as the first agent in the orexin receptor antagonist group in the form of film-coated tablets (Belsomra). Structure and properties Suvorexant (C23H23ClN6O2, Mr = 450.9 g/mol) exists as a white powder that is insoluble in water. It is a benzoxazole, diazepane and triazole derivative. Effects … Suvorexant
Products Melatonin is commercially available in the form of sustained-release tablets (Circadin, Slenyto). It was approved as a prescription drug in the EU in 2007 and in many countries in 2009. Melatonin may also be included in magistral formulations. Slenyto was registered in many countries in 2019. In some countries – for example, the United … Melatonin: Drug Effects, Side Effects, Dosage and Uses
Products In many countries, there are no drugs containing carisoprodol on the market. In other countries, it is available in tablet form (Soma, Somadril). It has been approved in the United States since 1959. In 2007, the European Medicines Agency concluded that the benefits of the drug did not outweigh the risks. Structure and properties … Carisoprodol
Products Efavirenz is commercially available as film-coated tablets and as an oral solution (Stocrin, combination products, generics). It has been approved in many countries since 2001. Structure and properties Efavirenz (C14H9ClF3NO2, Mr = 315.7 g/mol) exists as a white to light pink crystalline powder that is practically insoluble in water. It has a non-nucleoside structure … Efavirenz
Products Prazepam is commercially available in tablet form (Demetrin). It has been approved in many countries since 1977. Structure and properties Prazepam (C19H17ClN2O, Mr = 324.8 g/mol) exists as a white crystalline powder that is practically insoluble in water. It carries a cyclopropyl group. Effects Prazepam (ATC N05BA11) has antianxiety, sedative, relaxant, and depressant properties. … Prazepam
Products Encorafenib was approved in capsule form in the United States and EU in 2018 and in many countries in 2019 (Braftovi). Structure and properties Encorafenib (C22H27ClFN7O4S, Mr = 540.0 g/mol) exists as a white powder that is somewhat soluble in water only at low pH. Effects Encorafenib (ATC L01XE46) has antitumor and antiproliferative properties. … Encorafenib
Products Omeprazole is commercially available in tablet, capsule, and injection/infusion forms and has been approved in many countries since 1988. In addition to the original Antramups, generics and the -enantiomer esomeprazole (Nexium) are also commercially available. At the end of March 2010, after pantoprazole, omeprazole was also approved for self-medication in many countries. In the … Omeprazole: Drug Effects, Side Effects, Dosage and Uses
Products Fedratinib was approved in the United States in 2019 in capsule form (Inrebic). Structure and properties Fedratinib is present in the drug as dihydrochloride and monohydrate (fedratinib dihydrochloride monohydrate). Effects Fedratinib has antiproliferative properties. The effects are due to selective inhibition of Janus kinases 2 (JAK2). These are intracellular enzymes that belong to the … Fedratinib
Products Oritavancin was approved in the United States in 2014 as an infusion preparation (Orbactiv). The drug has not yet been registered in many countries. Structure and properties Oritavancin is present in drugs as oritavancin phosphate (C86H97N10O26Cl3 – 2H3PO4, Mr = 1989.1 g/mol) is present, a complex semisynthetically produced lipoglycopeptide structurally related to other glycopeptide … Oritavancin
Products Macitentan is commercially available in the form of film-coated tablets (Opsumit). It was approved in the United States in October 2013 and in many countries in 2014. Macitentan was launched as a successor to bosentan (Tracleer) as it loses patent protection. Structure and properties Macitentan (C19H20Br2N6O4S, Mr = 588.3 g/mol) is a brominated pyrimidine … Macitentan
Products Gliclazide has been commercially available in sustained-release tablet form and approved in many countries since 1978. The sustained-release dosage forms entered the market in 2001. In addition to the original Diamicron MR, sustained-release generics have been available since 2008. Sales of the non-retarded Diamicron 80 mg were discontinued in 2012. Structure and properties Gliclazide … Gliclazide
Products Tofacitinib was approved in the United States in November 2012, in many countries in 2013, and in the EU in 2017 in film-coated tablet form (Xeljanz). The European Medicines Agency initially rejected the approval in April 2013. However, baricitinib was approved. In the United States, additional sustained-release film-coated tablets are available that are taken … Tofacitinib
